This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Pulmonary Arterial Hypertension Treatment Market

Market Insights on Pulmonary Arterial Hypertension Treatment covering sales outlook, demand forecast & up-to-date key trends

Pulmonary Arterial Hypertension Treatment Market By Drug (Vasodilators, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), Soluble Guanylate Cyclase (SGC) Stimulator), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region - Forecast 2022 - 2028

Pulmonary Arterial Hypertension Treatment Market Outlook (2022-2028)

[260 Pages Report] Sales in the global pulmonary arterial hypertension treatment market are slated to top US$ 5.7 Bn in 2022. Expanding at a healthy 2.5% CAGR, the market size is projected to total US$ 6.6 Bn by 2028.

Attribute

Details

Pulmonary Arterial Hypertension Treatment Market Estimated Size 2022

US$ 5.7 Bn

Pulmonary Arterial Hypertension Treatment Market Value-based CAGR (2022-2028)

~2.5%

Pulmonary Arterial Hypertension Treatment Market Size in Projected 2028

US$ 6.6 Bn

Increasing government support to create orphan drugs and surging cases of COVID-19 around the world are expected to drive the sales in the global market. Apart from this, the presence of a large population above the age of 60 years with lower immunity level who are often more vulnerable to pulmonary arterial hypertension and other related diseases, might fuel demand for effective treatment.

The strong novel drug combination and product pipeline awaiting approval from the government agencies are anticipated to bolster the growth in the pulmonary arterial hypertension treatment market. Also, the increasing number of children suffering from untreated pulmonary arterial hypertension is likely to create growth opportunities in this market.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

2.46%

H1, 2022 Projected

2.50%

H1, 2022 Outlook

2.20%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 30 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 26 ↓

The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 30 units. A negative BPS growth in H1-2022 over H1-2021 by 26 Basis Point Share (BPS) is demonstrated by the global pulmonary arterial hypertension treatment market, as per Future Market Insights study.

Key developments in the market include stem cell-based therapy, gene transfer and epigenetic therapy for treatment of patients with pulmonary hypertension. The market is subject to changes associated with the regulatory dynamics and impositions for drugs and biologics, and licensing requirements for product distribution, as per macro and industry standards.

Oral therapy is widely used in management of pulmonary arterial hypertension. Oral therapy has many drawbacks, such as headaches, flushing, and abnormalities of the liver enzymes, dyspepsia, and diarrhoea. 

When compared to alternative routes of administration, oral therapy has a direct impact on the changing BPS levels.  This is because the adoption of oral therapy shows poor patient compliance.  However, growing treatment options for pulmonary arterial hypertension treatment will provide opportunistic growth to the market players in the forecast duration.

2017-2022 Pulmonary Arterial Hypertension Treatment Market Outlook in Comparison to 2022-2028 Growth Forecast

The pulmonary arterial hypertension treatment market is expected to register 2.5% CAGR between 2022 and 2028, up from 2.3% CAGR recorded during 2017-2022.

Increasing number of drug pipelines and rising healthcare spending in various parts of the globe are likely to drive the market. Demand also will surge on account of the increasing geriatric population and globally surging prevalence of hypertension.

As per the National Organization for Rare Disorders (NORD), this type of hypertension mainly affects females between the age group of 30 to 60 years. In the U.S. and the U.K., new cases are projected to occur in one to two individuals per million every year. This surging prevalence of the condition is set to drive the market in the near future.

Pulmonary Arterial Hypertension Treatment Market Download Report Brochure

Rising investments by various pharmaceutical companies towards the development of new drugs is likely to affect the market positively over the forecast period. In February 2021, for instance, United Therapeutics, a publicly traded biotechnology company, launched Remunity Pump for Remodulin for treating patients with this condition. Such innovations in the market are anticipated to accelerate the growth.

How has COVID-19 Augmented Demand for Pulmonary Arterial Hypertension Treatment?

The increasing awareness amongst people regarding the availability of numerous treatment alternatives for pulmonary arterial hypertension and the launch of technologically advanced devices to treat this condition are projected to bolster the market in the near future.

Governments of various countries across the globe are providing funds for the development and distribution of high-quality therapies for the treatment of this condition. In addition to that, the outbreak of the COVID-19 pandemic is likely to drive the growth in this market.

COVID-19 can often lead to cardiovascular and pulmonary complications. Various clinical research studies based on SARS-CoV-2 showcased that the virus is capable of changing the pulmonary hemodynamics through the mechanisms of venous thromboembolism, endothelial dysfunction, thrombotic microangiopathy, and vascular leak.

In January 2021, for instance, the National Center for Biotechnology Information (NCBI) published a study which states that those patients who died of COVID-19, exhibited thickened pulmonary vascular walls. This shows that in future, SARS-CoV-2 can trigger the high susceptibility of infected individuals to developing pulmonary arterial hypertension.

Spurred by the aforementioned factors, the need for novel treatment options is expected to grow over the forthcoming years worldwide.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-wise Insights

Which are the Factors Driving U.S. Pulmonary Arterial Hypertension Treatment Market?

The presence of a well-developed healthcare infrastructure is expected to facilitate access to innovative therapeutics in the U.S. over the forecast period. North America pulmonary arterial hypertension treatment market is set to account for approximately 33.9% of the share in 2022, says FMI.

Moreover, the supportive government initiatives to implement a well-planned reimbursement structure, high diagnosis rate, and increasing awareness regarding this condition are anticipated to propel the growth in the U.S.

Apart from that, the surging prevalence of this condition in the U.S. owing to high alcohol consumption, rapid adoption of a sedentary lifestyle, and increasing smoking habits among people is expected to accelerate the market.

How is the U.K. Pulmonary Arterial Hypertension Treatment Market Faring?

The U.K. is set to grow at a fast pace in the upcoming years because of the presence of prominent organizations, such as the European Society of Cardiology and the European Medicines Agency (EMA). These organizations are driving the early and preventive diagnosis of hypertension. Western Europe pulmonary arterial hypertension treatment market is likely to generate around 21.1% of the share in 2022, predicts FMI.

The increasing prevalence of HIV in the U.K. is also projected to surge the probability of the development of this condition. According to the National Aids Trust, in 2019, 98% of people were diagnosed with HIV in the U.K., whereas 1 in 16 people living with the virus in this country were unaware about the condition. This number is anticipated to increase in the near future and augment the growth.

Will the India Pulmonary Arterial Hypertension Treatment Market Emerge as a Lucrative Pocket?

The increasing prevalence of diabetes is expected to drive the market in India in the near future. As per FMI, Asia Pacific excluding Japan (APECJ) pulmonary arterial hypertension treatment market is projected to account for 9.4% of the share in 2020.

According to the data published by the World Health Organization (WHO), approximately 8.7% of the diabetic population in India belongs to the age group of 20 to 70 years. The higher adoption of unhealthy diet and increasing life expectancy are a couple of significant factors anticipated to propel the cases of diabetes in the country and drive the market.

Further, the increasing number of research grant programs by the government to promote clinical research in the field of pulmonary hypertension is set to support the market in India.

Category-wise Insights

Why would ERAs Dominate the Pulmonary Arterial Hypertension Treatment Market?

Based on drug type, the Endothelin Receptor Antagonists (ERA) segment is anticipated to account for around 47.6% of the global market share in 2022, says FMI. The increasing adoption of ERAs as a targeted therapy to dilate blood vessels, slow the progression of pulmonary arterial hypertension, and reverse the damage of the lungs and heart are set to propel this segment over the forthcoming years.

Further, ERAs are highly recommended by healthcare professionals for reducing the amount of endothelin in blood vessels as many clinical studies have revealed that patients with hypertension produce a large amount of this peptide. Apart from that, increasing investments by government and private agencies in research and development activities to introduce novel ERAs are anticipated to bolster this segment.

Which is the Leading Distribution Channel in Pulmonary Arterial Hypertension Treatment Market?

In terms of distribution channel, the hospital pharmacies segment is projected to remain at the forefront in the assessment period. This growth is attributable to the increasing patient visits to hospitals for the treatment for pulmonary arterial hypertension.

In addition, the rising sales of prescribed drugs for the treatment of this disorder from hospital pharmacies is expected to support the growth of this segment. Besides, many government agencies are likely to set up awareness campaigns in hospital settings to educate the general public about this condition and the drugs available for treatment. This factor is also estimated to boost the growth of the segment in the near future.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competition Landscape

Most of the key players present in the pulmonary arterial hypertension market are focusing on investing huge sums in research and development activities to come up with state-of-the-art drugs. Some of the other players are striving to gain fast track approvals from the regulatory bodies for the marketing and distribution of their novel drugs.

For instance,

  • In December 2021, Aerovate Therapeutics, a clinical stage biopharmaceutical company based in the U.S., started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with pulmonary arterial hypertension. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
  • In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the U.S. Food and Drug Administration (USFDA) for the marketing of Selexipag tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).

Scope of Report

Attribute

Details

Forecast Period

2017-2022

Historical Data Available for

2022-2028

Market Analysis

Units for Volume and US$ Mn for Value

Key Regions Covered

North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and the Middle East & Africa.

Key Countries Covered

United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others.

Key Market Segments Covered

Drug Type, Distribution Channel, and Region

Key Companies Profiled

Pricing

Available upon Request

Pulmonary Arterial Hypertension Treatment Market by Category

Drug Type :

  • Vasodilators
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Endothelin Receptor Antagonists (ERA)
  • Soluble Guanylate Cyclase (SGC) Stimulator

Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • China
  • Japan
  • Middle East & Africa

Frequently Asked Questions

The global pulmonary arterial hypertension treatment market is expected to reach a valuation of US$ 6.6 Bn in 2028.

The global pulmonary arterial hypertension treatment market grew at a healthy 2.3% CAGR between 2017 and 2022.

The increasing prevalence of COVID-19 infection, rising number of pipeline drugs, and government investments in R&D activities are the key trends boosting the pulmonary arterial hypertension treatment market.

United Therapeutics Ltd., Bayer AG, Actelion Ltd., Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd., and Johnson & Johnson Services, Inc. are some of the leading players present in the global pulmonary arterial hypertension treatment market.

The pulmonary arterial hypertension treatment market in North America is anticipated to account for 33.9% of the global market share in 2022.

The Japan pulmonary arterial hypertension treatment market is projected to account for 9.5% of the market share in the forecast period.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. Hidden Facts

    1.4. FMI Analysis and Recommendations

    1.5. Wheel of Fortune

2. Market Introduction

    2.1. Evolution

    2.2. Market Definition

    2.3. Market Taxonomy

3. Pulmonary Arterial Hypertension Treatment Market Analysis

    3.1. Overview of Pulmonary Arterial Hypertension Treatments

    3.2. Macro-Economic Factors

4. Market Background

    4.1. Value Chain

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity Analysis

    4.3. Regulatory Scenario

    4.4. Pipeline Assessment

    4.5. Reimbursement Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook

    6.1. Gross Domestic Product by Region & Country, 2016 – 2021

    6.2. Disease epidemiology Analysis

7. North America Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    7.1. Introduction

    7.2. Regional Market Trends

    7.3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022

        7.3.1. U.S.

        7.3.2. Canada

    7.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    7.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        7.5.1. Vasodilators

        7.5.2. Endothelin receptor antagonists

        7.5.3. PDE-5

        7.5.4. Soluble guanylate cyclase (SGC) stimulator

    7.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    7.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        7.7.1. Hospitals

        7.7.2. Retail Pharmacies

        7.7.3. Online Pharmacies

    7.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    7.9. Market Attractiveness Analysis

        7.9.1. By Country

        7.9.2. By Drug Class

        7.9.3. By Distribution Channel

    7.10. Key Market Participants – Intensity Mapping

    7.11. Drivers and Restraints – Impact Analysis

8. Latin America Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    8.1. Introduction

    8.2. Regional Market Trends

    8.3. Historical Market Size (US$ Mn) Trends Analysis By Country, 2017-2022

        8.3.1. Argentina

        8.3.2. Brazil

        8.3.3. Mexico

        8.3.4. Rest of Latin America

    8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    8.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        8.5.1. Vasodilators

        8.5.2. Endothelin receptor antagonists

        8.5.3. PDE-5

        8.5.4. Soluble guanylate cyclase (SGC) stimulator

    8.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    8.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        8.7.1. Hospitals

        8.7.2. Retail Pharmacies

        8.7.3. Online Pharmacies

    8.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    8.9. Market Attractiveness Analysis

        8.9.1. By Country

        8.9.2. By Drug Class

        8.9.3. By Distribution Channel

    8.10. Key Market Participants – Intensity Mapping

    8.11. Drivers and Restraints – Impact Analysis

9. Western Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    9.1. Introduction

    9.2. Regional Market Trends

    9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2017-2022

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Nordic Countries

        9.3.7. BENELUX

        9.3.8. Rest of Western Europe

    9.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    9.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        9.5.1. Vasodilators

        9.5.2. Endothelin receptor antagonists

        9.5.3. PDE-5

        9.5.4. Soluble Guanylate Cyclase (SGC) stimulator

    9.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    9.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        9.7.1. Hospitals

        9.7.2. Retail Pharmacies

        9.7.3. Online Pharmacies

    9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    9.9. Market Attractiveness Analysis

        9.9.1. By Country

        9.9.2. By Drug Class

        9.9.3. By Distribution Channel

    9.10. Key Market Participants – Intensity Mapping

    9.11. Drivers and Restraints – Impact Analysis

10. Eastern Europe Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    10.1. Introduction

    10.2. Regional Market Trends

    10.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2017-2022

        10.3.1. Russia

        10.3.2. Poland

        10.3.3. Rest of Eastern Europe

    10.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    10.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        10.5.1. Vasodilators

        10.5.2. Endothelin receptor antagonists

        10.5.3. PDE-5

        10.5.4. Soluble guanylate cyclase (SGC) stimulator

    10.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    10.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        10.7.1. Hospitals

        10.7.2. Retail Pharmacies

        10.7.3. Online Pharmacies

    10.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    10.9. Market Attractiveness Analysis

        10.9.1. By Country

        10.9.2. By Drug Class

        10.9.3. By Distribution Channel

    10.10. Key Market Participants – Intensity Mapping

    10.11. Drivers and Restraints – Impact Analysis

11. Asia Pacific Excluding China & Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    11.1. Introduction

    11.2. Regional Market Trends

    11.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2017-2022

        11.3.1. India

        11.3.2. Australia and New Zealand

        11.3.3. ASEAN Countries

        11.3.4. Rest of Asia Pacific

    11.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    11.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        11.5.1. Vasodilators

        11.5.2. Endothelin receptor antagonists

        11.5.3. PDE-5

        11.5.4. Soluble guanylate cyclase (SGC) stimulator

    11.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    11.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        11.7.1. Hospitals

        11.7.2. Retail Pharmacies

        11.7.3. Online Pharmacies

    11.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    11.9. Market Attractiveness Analysis

        11.9.1. By Country

        11.9.2. By Drug Class

        11.9.3. By Distribution Channel

    11.10. Key Market Participants – Intensity Mapping

    11.11. Drivers and Restraints – Impact Analysis

12. China Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        12.2.1. Vasodilators

        12.2.2. Endothelin receptor antagonists

        12.2.3. PDE-5

        12.2.4. Soluble guanylate cyclase (SGC) stimulator

    12.3. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    12.4. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        12.4.1. Hospitals

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Distribution Channel

    12.7. Key Market Participants – Intensity Mapping

    12.8. Drivers and Restraints – Impact Analysis

13. Japan Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        13.2.1. Vasodilators

        13.2.2. Endothelin receptor antagonists

        13.2.3. PDE-5

        13.2.4. Soluble guanylate cyclase (SGC) stimulator

    13.3. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    13.4. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        13.4.1. Hospitals

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Distribution Channel

    13.7. Key Market Participants – Intensity Mapping

    13.8. Drivers and Restraints – Impact Analysis

14. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    14.1. Introduction

    14.2. Regional Market Trends

    14.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2017-2022

        14.3.1. GCC Countries

        14.3.2. South Africa

        14.3.3. Rest of MEA

    14.4. Market Size (US$ Mn) Forecast By Country, 2022-2028

    14.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        14.5.1. Vasodilators

        14.5.2. Endothelin receptor antagonists

        14.5.3. PDE-5

        14.5.4. Soluble guanylate cyclase (SGC) stimulator

    14.6. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    14.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2017-2022

        14.7.1. Hospitals

        14.7.2. Retail Pharmacies

        14.7.3. Online Pharmacies

    14.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028

    14.9. Market Attractiveness Analysis

        14.9.1. By Country

        14.9.2. By Drug Class

        14.9.3. By Distribution Channel

    14.10. Key Market Participants – Intensity Mapping

    14.11. Drivers and Restraints – Impact Analysis

15. Forecast Factors: Relevance and Impact

16. Forecast Assumptions

17. Competition Landscape

    17.1. Market Structure

    17.2. Competition Intensity Mapping By Market Taxonomy

    17.3. Competition Dashboard

    17.4. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

        17.4.1. United Therapeutics Ltd.

            17.4.1.1. Overview

            17.4.1.2. Key Financials

            17.4.1.3. Product and Application Portfolio

            17.4.1.4. Recent Developments

            17.4.1.5. Strategy

            17.4.1.6. SWOT Analysis

        17.4.2. Bayer AG

            17.4.2.1. Overview

            17.4.2.2. Key Financials

            17.4.2.3. Product and Application Portfolio

            17.4.2.4. Recent Developments

            17.4.2.5. Strategy

            17.4.2.6. SWOT Analysis

        17.4.3. Actelion Ltd.

            17.4.3.1. Overview

            17.4.3.2. Key Financials

            17.4.3.3. Product and Application Portfolio

            17.4.3.4. Recent Developments

            17.4.3.5. Strategy

            17.4.3.6. SWOT Analysis

        17.4.4. Pfizer, Inc

            17.4.4.1. Overview

            17.4.4.2. Key Financials

            17.4.4.3. Product and Application Portfolio

            17.4.4.4. Recent Developments

            17.4.4.5. Strategy

            17.4.4.6. SWOT Analysis

        17.4.5. Gilead Sciences, Inc.

            17.4.5.1. Overview

            17.4.5.2. Key Financials

            17.4.5.3. Product and Application Portfolio

            17.4.5.4. Recent Developments

            17.4.5.5. Strategy

            17.4.5.6. SWOT Analysis

        17.4.6. GlaxoSmithKline plc

            17.4.6.1. Overview

            17.4.6.2. Key Financials

            17.4.6.3. Product and Application Portfolio

            17.4.6.4. Recent Developments

            17.4.6.5. Strategy

            17.4.6.6. SWOT Analysis

        17.4.7. Teva Pharmaceuticals Inc.

            17.4.7.1. Overview

            17.4.7.2. Key Financials

            17.4.7.3. Product and Application Portfolio

            17.4.7.4. Recent Developments

            17.4.7.5. Strategy

            17.4.7.6. SWOT Analysis

        17.4.8. Eli Lilly and Company

            17.4.8.1. Overview

            17.4.8.2. Key Financials

            17.4.8.3. Product and Application Portfolio

            17.4.8.4. Recent Developments

            17.4.8.5. Strategy

            17.4.8.6. SWOT Analysis

        17.4.9. Steady Med Ltd.

            17.4.9.1. Overview

            17.4.9.2. Key Financials

            17.4.9.3. Product and Application Portfolio

            17.4.9.4. Recent Developments

            17.4.9.5. Strategy

            17.4.9.6. SWOT Analysis

        17.4.10. Johnson & Johnson Services, Inc

            17.4.10.1. Overview

            17.4.10.2. Key Financials

            17.4.10.3. Product and Application Portfolio

            17.4.10.4. Recent Developments

            17.4.10.5. Strategy

            17.4.10.6. SWOT Analysis

18. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028, By Region

    18.1. Introduction / Key Findings

    18.2. Historical Market Size (US$ Mn) By Region

        18.2.1. North America

        18.2.2. Western Europe

        18.2.3. Eastern Europe

        18.2.4. Latin America

        18.2.5. Asia Pacific Excluding China & Japan

        18.2.6. China

        18.2.7. Japan

        18.2.8. Middle East and Africa

    18.3. Market Size (US$ Mn) Forecast By Region

        18.3.1. North America

        18.3.2. Western Europe

        18.3.3. Eastern Europe

        18.3.4. Latin America

        18.3.5. Asia Pacific Excluding China & Japan

        18.3.6. China

        18.3.7. Japan

        18.3.8. Middle East and Africa

    18.4. Market Attractiveness Analysis By Region

19. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028, By Drug Class

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2017-2022

        19.2.1. Vasodilators

        19.2.2. Endothelin receptor antagonists

        19.2.3. PDE-5

        19.2.4. Soluble guanylate cyclase (SGC) stimulator

    19.3. Market Size (US$ Mn) and Volume Forecast By Drug Class, 2022-2028

    19.4. Key Trends / Developments

    19.5. Market Attractiveness Analysis By Drug Class Type

20. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028, By Distribution Channels

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Analysis By Distribution Channels , 2012-2016

        20.2.1. Hospitals

        20.2.2. Retail Pharmacies

        20.2.3. Online Pharmacies

    20.3. Market Size (US$ Mn) and Forecast By Distribution Channels , 2017-2027

        20.3.1. Hospitals

        20.3.2. Retail Pharmacies

        20.3.3. Online Pharmacies

    20.4. Key Trends / Developments

    20.5. Market Attractive Analysis By Distribution Channels

21. Global Pulmonary Arterial Hypertension Treatment Market Analysis 2017-2022 and Forecast 2022-2028

    21.1. Global Volume Analysis

    21.2. Market Size and Y-o-Y Growth

    21.3. Absolute $ Opportunity

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 04: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 05: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 06: North America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 07: Latin America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 08: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 09: Latin America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 10: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 11: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 12: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 13: Western Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 14: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 15: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 16: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 17: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 18: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 19: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 20: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 21: APECJ Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 22: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 23: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 24: China Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 25: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 26: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 27: Japan Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 28: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 29: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 30: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 31: MEA Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 32: Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Forecast By Region, 2013-2028

Table 33: Global Pulmonary Arterial Hypertension Treatment Market Size Value (US$ Mn) Analysis 2017-2022 and Forecast 2018–2028 , By Drug Type

Table 34: Global Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis 2017-2022 and Forecast 2018–2028, By Distribution Channel

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 04: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 05: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 06: North America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 07: Latin America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 08: North America Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 09: Latin America Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 10: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 11: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 12: Western Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 13: Western Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 14: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 15: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 16: Eastern Europe Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 17: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 18: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 19: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 20: APECJ Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 21: APECJ Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 22: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 23: China Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 24: China Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 25: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 26: Japan Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 27: Japan Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 28: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn)Analysis-2017-2022 and Forecast 2022-2028 By Country

Table 29: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Drug Type

Table 30: MEA Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis-2017-2022 and Forecast 2022-2028 By Distribution Channel

Table 31: MEA Pulmonary Arterial Hypertension Treatment Market Participants Presence (Intensity Mapping)

Table 32: Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Forecast By Region, 2013-2028

Table 33: Global Pulmonary Arterial Hypertension Treatment Market Size Value (US$ Mn) Analysis 2017-2022 and Forecast 2018–2028 , By Drug Type

Table 34: Global Pulmonary Arterial Hypertension Treatment Market size (US$ Mn) Analysis 2017-2022 and Forecast 2018–2028, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Pulmonary Arterial Hypertension Treatment Market Value Share 2018E, By Region

Figure 02: Global Pulmonary Arterial Hypertension Treatment Market Value Share, By Drug Class

Figure 03: Global Healthcare Expenditure in US$ Tn (2013–2020)

Figure 04: North America Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 05: North America Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 06: U.S. Pulmonary Arterial Hypertension Treatment, Market Size (US$ Mn) Analysis, 2017-2022

Figure 07: U.S. Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 08: Canada Pulmonary Arterial Hypertension Treatment, Market Size (US$ Mn) Analysis, 2017-2022

Figure 09: Canada Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 10: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 11: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 12: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 13: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 14: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 15: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 16: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 17: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 18: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 19: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 20: North America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 21: Latin America Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 22: Latin America Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 23: Brazil Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 24: Brazil Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 25: Mexico Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 26: Mexico Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 27: Argentina Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 28: Argentina Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 29: Rest of LATAM Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 30: Rest of LATAM Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 31: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 32: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 33: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 34: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 35: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 36: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 37: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 38: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 39: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 40: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 41: Latin America Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 42: Western Europe Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 43: Western Europe Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 44: Germany Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 45: Germany Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 46: U.K. Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 47: U.K. Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 48: France Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 49: France Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 50: Italy Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 51: Italy Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 52: Spain Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 53: Spain Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 54: Nordic Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 55: Nordic Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 56: BENELUX Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 57: BENELUX Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 58: Rest of Western Europe Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 59: Rest of Western Europe Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 60: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 61: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 62: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 63: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 64: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 65: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 66: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 67: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 68: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 69: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 70: Western Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 71: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 72: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 73: Russia Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 74: Russia Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 75: Poland Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 76: Poland Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 77: Rest of Eastern Europe Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 78: Rest of Eastern Europe Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 79: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 80: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 81: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 82: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 83: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 84: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 85: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 86: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 87: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 88: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 89: Eastern Europe Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 90: APECJ Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 91: APECJ Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 92: India Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 93: India Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 94: Australia & New Zealand Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 95: Australia & New Zealand Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 96: ASEAN Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 97: ASEAN Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 98: Rest of APECJ Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 99: Rest of APECJ Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 100: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 101: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 102: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 103: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 104: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 105: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 106: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 107: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 108: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 109: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 110: APECJ Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 111: China Pulmonary Arterial Hypertension Treatment Market Split By Drug Class (2018)

Figure 112: China Pulmonary Arterial Hypertension Treatment Market Split By Distribution Channel (2018)

Figure 113: China Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 114: China Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 115: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 116: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 117: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 118: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 119: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 120: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 121: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 122: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 123: China Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 124: China Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 125: Japan Pulmonary Arterial Hypertension Treatment Market Split By Drug Class (2018)

Figure 126: Japan Pulmonary Arterial Hypertension Treatment Market Split By Distribution Channel (2018)

Figure 127: Japan Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 128: Japan Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 129: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 130: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 131: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 132: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 133: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 134: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 135: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By sGC stimulator

Figure 136: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By sGC stimulator

Figure 137: Japan Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 138: Japan Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 139: MEA Pulmonary Arterial Hypertension Treatment Market Size Analysis, 2017-2022

Figure 140: MEA Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y growth, 2022-2028

Figure 141: GCC Countries Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 142: GCC Countries Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 143: South Africa Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 144: South Africa Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 145: Rest of MEA Pulmonary Arterial Hypertension Treatment , Market Size (US$ Mn) Analysis, 2017-2022

Figure 146: Rest of MEA Pulmonary Arterial Hypertension Treatment, Market Forecast & Y-o-Y Growth (%), 2022-2028

Figure 147: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By Vasodilators

Figure 148: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By Vasodilators

Figure 149: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By ERA

Figure 150: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By ERA

Figure 151: Pulmonary Arterial Hypertension Treatment Market Size (US$ Mn) Analysis, 2017-2022, By PDE-5

Figure 152: Pulmonary Arterial Hypertension Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028, By PDE-5

Figure 153: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Country, 2022-2028

Figure 154: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Class, 2022-2028

Figure 155: MEA Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 156: Global Pulmonary Arterial Hypertension Treatment Market Company Share Analysis (2017)

Figure 157: Global Pulmonary Arterial Hypertension Treatment Industry Structure

Figure 158: Global Pulmonary Arterial Hypertension Treatment Market Share, By Tier (2017)

Figure 159: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Region, 2022-2028

Figure 160: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Drug Type, 2022-2028

Figure 161: Global Pulmonary Arterial Hypertension Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028

Figure 162: Global Pulmonary Arterial Hypertension Treatment Market Value Analysis and Forecast, 2016–2028 (US$ Mn)

Figure 163: Global Pulmonary Arterial Hypertension Treatment Market Absolute $ Opportunity (US$ Mn), 2016–2028

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Pulmonary Arterial Hypertension Treatment Market